Table 3.

Adjusted hazard ratios of 3-year RFS by new pathology N stage group

New pathology N stage group	N	Events (%)	Model 1		Model 2		Model 3
			HR (95% CI)	P-value	HR (95% CI)	P Value	HR (95% CI)	P-value
Tumor deposit + lymph node metastases < 4	627	93(14.83)	1.0 (Ref.)		1.0 (Ref.)		1.0 (Ref.)
lymph node metastases ≥ 4	255	61(23.92)	1.94 (1.56, 2.42)	< 0.001	1.89 (1.50, 2.31)	0.009	1.86 (1.49, 2.33)	0.01
Tumor deposit + lymph node metastases ≥ 4	67	36(53.73)	1.98 (1.30, 3.00)	0.001	1.91 (1.28, 2.59)	0.001	1.88 (1.24, 2.87)	0.003

HR hazard ratios, Ref. reference

Model 1 was unadjusted

Model 2 was adjusted for age (< 60 vs. ≥ 60), body mass index (< 24 vs. ≥ 24), and sex (male vs. female)

Model 3 was adjusted for age (< 60 vs. ≥ 60), body mass index (< 24 vs. ≥ 24), sex (male vs. female), surgical approach (open resection vs. laparoscopic resection), location (right colon vs. left colon vs. rectum), tumor differentiation (well vs. moderate vs. poor-undifferentiated), mucinous type (yes vs. no), pathology T stage (T4 vs. T3 vs. T2 vs. T1), lymphovascular invasion (yes vs. no), perineural invasion (yes vs. no), adjuvant chemotherapy (yes vs. no), lymph node yield (≥ 12 vs. < 12), postoperative CEA, ng/mL (≤ 5 vs. > 5), postoperative CA19-9, ng/mL (≤ 37 vs. > 37), and tumor deposit (yes vs. no)